In the version of the article initially published, in Fig. 2b, the label “IIanalumab” was incorrect and has now been amended to “Ianalumab”. Additionally, the target of Ianalumab was incorrectly shown to be BAFF-R/BCMA/TACI, and the labels “Epratuzumab” and “Anifrolumab” originally both read “IIanalumab”. These errors have now been corrected in the HTML and PDF versions of the article.